Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Fluvoxamine
Drug ID BADD_D00950
Description Fluvoxamine is an antidepressant which functions pharmacologically as a selective serotonin reuptake inhibitor. Though it is in the same class as other SSRI drugs, it is most often used to treat obsessive-compulsive disorder. Fluvoxamine has been in use in clinical practice since 1983 and has a clinical trial database comprised of approximately 35,000 patients. It was launched in the US in December 1994 and in Japan in June 1999. As of the end of 1995, more than 10 million patients worldwide have been treated with fluvoxamine.
Indications and Usage Indicated predominantly for the management of depression and for Obsessive Compulsive Disorder (OCD) [FDA Label]. Has also been used in the management of bulimia nervosa [A250].
Marketing Status Prescription; Discontinued
ATC Code N06AB08
DrugBank ID DB00176
KEGG ID D07984
MeSH ID D016666
PubChem ID 5324346
TTD Drug ID D03HFG
NDC Product Code Not Available
Synonyms Fluvoxamine | Fluvoxadura | Fluvoxamin AL | Fluvoxamin beta | Fluvoxamin Stada | Fluvoxamin-neuraxpharm | Fluvoxamin neuraxpharm | Fluvoxamin-ratiopharm | Fluvoxamin ratiopharm | ratio-Fluvoxamine | ratio Fluvoxamine | Fluvoxamina Geminis | Geminis, Fluvoxamina | Fluvoxamine Maleate | Fluvoxamine Maleate, (E)-Isomer | Fluvoxamine, (Z)-Isomer | Luvox | Floxyfral | Fevarin | Dumirox | Faverin | Novo-Fluvoxamine | Novo Fluvoxamine | Nu-Fluvoxamine | Nu Fluvoxamine | PMS-Fluvoxamine | PMS Fluvoxamine | Desiflu | DU-23000 | DU 23000 | DU23000
Chemical Information
Molecular Formula C15H21F3N2O2
CAS Registry Number 54739-18-3
SMILES COCCCCC(=NOCCN)C1=CC=C(C=C1)C(F)(F)F
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Poisoning and toxicityCytochrome P450 2D6P10635T57392Not Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Weight decreased13.15.01.005--
Weight increased13.15.01.006--
White blood cell count decreased13.01.06.012--
Withdrawal syndrome19.07.02.005; 08.06.02.012--Not Available
Yawning22.02.05.017--Not Available
Homicidal ideation19.05.01.008--Not Available
Self-injurious ideation19.12.01.007--Not Available
Acute coronary syndrome24.04.04.011; 02.02.02.015--Not Available
Lymphatic disorder01.09.01.003--Not Available
Musculoskeletal stiffness15.03.01.005--Not Available
Musculoskeletal discomfort15.03.04.001--Not Available
Inappropriate antidiuretic hormone secretion14.05.07.001; 05.03.03.001--Not Available
Depressive symptom19.15.02.003--Not Available
Affect lability19.04.01.001--Not Available
Haemorrhage24.07.01.002--Not Available
Obsessive rumination19.06.05.006--Not Available
Rectal tenesmus15.05.03.011; 07.03.03.001--Not Available
Female sexual dysfunction21.03.02.004; 19.08.05.001--Not Available
Major depression19.15.01.003--Not Available
Heart alternation02.03.02.023--Not Available
Nuchal rigidity17.05.02.006; 15.05.04.005--Not Available
Muscle relaxant therapy25.16.01.001--Not Available
Disturbance in sexual arousal19.08.04.003--Not Available
Angiopathy24.03.02.007--Not Available
Urine output increased13.13.03.002--Not Available
Breast disorder21.05.04.004--Not Available
Cardiac disorder02.01.01.003--Not Available
Embolism24.01.01.009--
Malnutrition14.03.02.004--Not Available
Mental disorder19.07.01.002--Not Available
The 13th Page    First    Pre   13 14    Next   Last    Total 14 Pages